Dr Reddys surges on getting US FDA nod for Azacitidine Injection

18 Sep 2013 Evaluate

 Dr Reddys is currently trading at Rs. 2330.35, up by 25.20 points or 1.09% from its previous closing of Rs. 2305.15 on the BSE.

The scrip opened at Rs. 2310.00 and has touched a high and low of Rs. 2343.00 and Rs. 2310.00 respectively. So far 5,630 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2400.75 on 15-Jul-2013 and a 52 week low of Rs. 1617.00 on 27-Sep-2012.

Last one week high and low of the scrip stood at Rs. 2323.00 and Rs. 2161.00 respectively. The current market cap of the company is Rs. 39,615 crore.

The promoters holding in the company stood at 25.53% while Institutions and Non-Institutions held 41.53% and 15.79% respectively.

Pharma major Dr Reddys Laboratories has received US Food and Drug Administration (FDA) approval for Azacitidine Injection 100 mg/vial, a bioequivalent generic version of VIDAZA (azacitidine for injection) on September 16, 2013. The launch of product in the market is planned in the near-term.

The VIDAZA brand had U.S. sales of approximately $378.5 Million for the most recent twelve months ending July 2013 according to IMS Health.

Dr Reddy's Azacitidine for Injection 100 mg/vial is available in single use-vials.

Dr. Reddys Lab Share Price

1275.05 -1.95 (-0.15%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×